Licensing · Global (LMICs) · Announced 21 Jan 2026

Galenicum → Lupin

Galenicum licensed its generic semaglutide injection to Lupin for 23 countries, including Southeast Asian markets; Galenicum develops, makes and supplies, while Lupin registers and sells.

Parties: Galenicum (Spain) → Lupin (India)

Deal type
Licensing
Value
Undisclosed
Territory
23 countries (not listed), including markets in Canada, Europe, Southeast Asia and Latin America
Therapeutic area
Metabolic / Diabetes
Asset
Semaglutide
Announced
21 Jan 2026

Our analysis

Why this matters

On 21 January 2026, Lupin and Spain's Galenicum signed a licence and supply agreement for generic semaglutide injection in 23 countries. Galenicum is responsible for development, manufacturing and supply; Lupin, through its subsidiary Lupin Atlantis Holdings, handles regulatory submissions, approvals, commercialisation and distribution. The release does not list the 23 countries but names markets in Canada, Europe, Southeast Asia and Latin America. Semaglutide is a GLP-1 receptor agonist used in type 2 diabetes and, in some formulations, weight management. No financial terms were disclosed.

Semaglutide patents begin to expire in several markets from 2026, opening a large generic opportunity.

The full analysis is free to read with a work email on this page.

Source: Lupin press release

More deals involving Galenicum or Lupin

Latest deals

All Global (LMICs) deals → · All licensing deals → · Browse all emerging-market pharma deals →